0R29 Stock Chart & Stats
$338.66
$0.94(0.26%)
At close: 4:00 PM EDT
$338.66
$0.94(0.26%)
Day’s Range― - ―
52-Week Range$328.37 - $603.32
Previous CloseN/A
Volume48.00
Average Volume (3M)4.70K
Market Cap
$138.97B
Enterprise Value$136.97K
Total Cash (Recent Filing)$5.22B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)45.3
Beta0.91
Next Earnings
Oct 20, 2026EPS Estimate
2.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.85
Shares Outstanding353,278,050
10 Day Avg. Volume9,126
30 Day Avg. Volume4,699
Financial Highlights & Ratios
PEG Ratio3.17
Price to Book (P/B)11.34
Price to Sales (P/S)20.08
P/FCF Ratio81.16
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$488.14Price Target Upside44.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering24
EPS Forecast (FY)10.8
Revenue Forecast (FY)$11.76B
Bulls Say, Bears Say
Bulls Say
Recurring Revenue Model And High Recurring MixA durable razor‑and‑blades model (systems drive long‑lived installed base; instruments/accessories and service recur per procedure) creates predictable revenue streams and high margin repeat economics. High recurring mix supports cash visibility and long‑term margin resilience.
Very Strong Balance Sheet And Cash GenerationNear‑zero leverage and multi‑billion FCF capacity provide structural financial flexibility to fund R&D, buybacks, and withstand cycle swings. Strong cash conversion lowers refinancing risk and underpins durable investment in product development and commercialization.
Expanding Installed Base And Ongoing Product InnovationA growing installed base increases future consumable and service volumes, reinforcing recurring revenue. Continuous product upgrades (da Vinci 5, ION, SP/XiR) raise switching costs and clinical adoption, sustaining long‑term competitive advantages and market share gains.
Bears Say
Revenue Growth DecelerationSlowing top‑line expansion reduces the leverage in a high‑margin model and increases reliance on margin gains and share buybacks to drive returns. Persistent deceleration can compress future recurring revenue additions and limit long‑run operating leverage benefits.
China And International Market PressuresSustained weakness or pricing pressure in China and pockets of international capital constraint can materially reduce system placements and future recurring sales. Geographic headwinds constrain addressable growth and raise execution risk for multi‑year expansion plans.
Unquantified Extended‑use Instrument Program RiskIf extended‑use instruments materially reduce per‑procedure consumable purchases, the core razor‑and‑blades revenue stream could be eroded. The unquantified nature raises structural margin and revenue visibility risks until adoption rates and pricing impacts are disclosed and modeled.
Intuitive Surgical News
0R29 FAQ
What was Intuitive Surgical’s price range in the past 12 months?
Intuitive Surgical lowest share price was $328.37 and its highest was $603.32 in the past 12 months.
What is Intuitive Surgical’s market cap?
Intuitive Surgical’s market cap is $138.97B.
When is Intuitive Surgical’s upcoming earnings report date?
Intuitive Surgical’s upcoming earnings report date is Oct 20, 2026 which is in 68 days.
How were Intuitive Surgical’s earnings last quarter?
Intuitive Surgical released its earnings results on Jul 16, 2026. The company reported $2.8 earnings per share for the quarter, beating the consensus estimate of $2.511 by $0.289.
Is Intuitive Surgical overvalued?
According to Wall Street analysts Intuitive Surgical’s price is currently Undervalued.
Does Intuitive Surgical pay dividends?
Intuitive Surgical pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Intuitive Surgical dividends here
What is Intuitive Surgical’s EPS estimate?
Intuitive Surgical’s EPS estimate is 2.64.
How many shares outstanding does Intuitive Surgical have?
Intuitive Surgical has 353,278,050 shares outstanding.
What happened to Intuitive Surgical’s price movement after its last earnings report?
Intuitive Surgical reported an EPS of $2.8 in its last earnings report, beating expectations of $2.511. Following the earnings report the stock price went down -12.613%.
Which hedge fund is a major shareholder of Intuitive Surgical?
Currently, no hedge funds are holding shares in GB:0R29
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intuitive Surgical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$488.14 (44.14% Upside)
$488.14 (44.14% Upside)
Blogger Sentiment
Bullish
GB:0R29 Sentiment 90%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.54%
Trailing 12-Months
Company Description
Intuitive Surgical
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.
0R29 Company Deck
0R29 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: robust revenue (+19%), strong profitability (42% non-GAAP operating margin), healthy procedure growth (total +16%) and capital placements (468 da Vinci systems), plus strong cash flow. The company also highlighted meaningful product progress (da Vinci 5 updates, SP and XiR momentum, ION adoption) and clinical evidence supporting adoption. Key risks were noted but were mostly market- and policy-driven (U.S. patient coverage dynamics, China tender and pricing pressure), some procedure-mix headwinds (bariatrics) and an unquantified impact from the extended-use instrument program. Overall, the positive metrics and growth drivers materially outweigh the challenges discussed.View all GB:0R29 earnings summaries0R29 Revenue Breakdown
67.72% U.S.
32.28% Outside of U.S
0R29 Stock 12 Month Forecast
Average Price Target
$488.14
▲(44.14% Upside)